Sunitinib versus pazopanib para el tratamiento del carcinoma de células renales metastásico: experiencia en 2 hospitales turcos

Autor: Ekenel, M., Karabulut, S., Cil, I., Zırtıloglu, A., Aydın, E., Tural, D.

Publikováno v: In Actas Urologicas Espanolas January-February 2020 44(1):27-33

Comparison of second-line treatments in metastatic renal cell carcinoma patients: A single-center experience.

Autor: Pehlivan M; Zonguldak Ataturk State Hospital Department of Medical Oncology, Zonguldak, Istanbul, Turkey., Paksoy N; İstanbul University Institute of Oncology, Zonguldak, Istanbul, Turkey., Aydin E; İstanbul University Institute of Oncology, Zonguldak, Istanbul, Turkey., Basaran M; İstanbul University Institute of Oncology, Zonguldak, Istanbul, Turkey., Ekenel M; İstanbul University Institute of Oncology, Zonguldak, Istanbul, Turkey.

Publikováno v: Medicine [Medicine (Baltimore)] 2023 Oct 13; Vol. 102 (41), pp. e35245.

The use of bevacizumab in primary malignant tumors of the central nervous system: A single-center experience.

Autor: Pehlivan M; Department of Medical Oncology, Zonguldak Ataturk State Hospital, Zonguldak, Turkey., Ekenel M; Department of Medical Oncology, Istanbul University Institute of Oncology, Istanbul, Turkey.

Publikováno v: Medicine [Medicine (Baltimore)] 2023 Jul 28; Vol. 102 (30), pp. e34286.

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Autor: Burtness, B. Harrington, K.J. Greil, R. Soulières, D. Tahara, M. de Castro, G., Jr Psyrri, A. Basté, N. Neupane, P. Bratland, Å. Fuereder, T. Hughes, B.G.M. Mesía, R. Ngamphaiboon, N. Rordorf, T. Wan Ishak, W.Z. Hong, R.-L. González Mendoza, R. Roy, A. Zhang, Y. Gumuscu, B. Cheng, J.D. Jin, F. Rischin, D. Lerzo, G. Tatangelo, M. Varela, M. Zarba, J.J. Boyer, M. Gan, H. Gao, B. Hughes, B. Mallesara, G. Taylor, A. Burian, M. Barrios, C.H. de Castro Junior, D.O. Castro, G. Franke, F.A. Girotto, G. Lima, I.P.F. Nicolau, U.R. Pinto, G.D.J. Santos, L. Victorino, A.-P. Chua, N. Couture, F. Gregg, R. Hansen, A. Hilton, J. McCarthy, J. Soulieres, D. Ascui, R. Gonzalez, P. Villanueva, L. Torregroza, M. Zambrano, A. Holeckova, P. Kral, Z. Melichar, B. Prausova, J. Vosmik, M. Andersen, M. Gyldenkerne, N. Jurgens, H. Putnik, K. Reinikainen, P. Gruenwald, V. Laban, S. Aravantinos, G. Boukovinas, I. Georgoulias, V. Kwong, D. Al-Farhat, Y. Csoszi, T. Erfan, J. Horvai, G. Landherr, L. Remenar, E. Ruzsa, A. Szota, J. Billan, S. Gluck, I. Gutfeld, O. Popovtzer, A. Benasso, M. Bui, S. Ferrari, V. Licitra, L. Nole, F. Fujii, T. Fujimoto, Y. Hanai, N. Hara, H. Matsumoto, K. Mitsugi, K. Monden, N. Nakayama, M. Okami, K. Oridate, N. Shiga, K. Shimizu, Y. Sugasawa, M. Takahashi, M. Takahashi, S. Tanaka, K. Ueda, T. Yamaguchi, H. Yamazaki, T. Yasumatsu, R. Yokota, T. Yoshizaki, T. Kudaba, I. Stara, Z. Cheah, S.K. Aguilar Ponce, J. Gonzalez Mendoza, R. Hernandez Hernandez, C. Medina Soto, F. Buter, J. Hoeben, A. Oosting, S. Suijkerbuijk, K. Bratland, A. Brydoey, M. Alvarez, R. Mas, L. Caguioa, P. Querol, J. Regala, E.E. Tamayo, M.B. Villegas, E.M. Kawecki, A. Karpenko, A. Klochikhin, A. Smolin, A. Zarubenkov, O. Goh, B.C. Cohen, G. du Toit, J. Jordaan, C. Landers, G. Ruff, P. Szpak, W. Tabane, N. Brana, I. Iglesias Docampo, L. Lavernia, J. Mesia, R. Abel, E. Muratidu, V. Nielsen, N. Cristina, V. Rothschild, S. Wang, H.-M. Yang, M.-H. Yeh, S.-P. Yen, C.-J. Soparattanapaisarn, N. Sriuranpong, V. Aksoy, S. Cicin, I. Ekenel, M. Harputluoglu, H. Ozyilkan, O. Agarwala, S. Ali, H. Alter, R. Anderson, D. Bruce, J. Campbell, N. Conde, M. Deeken, J. Edenfield, W. Feldman, L. Gaughan, E. Goueli, B. Halmos, B. Hegde, U. Hunis, B. Jotte, R. Karnad, A. Khan, S. Laudi, N. Laux, D. Martincic, D. McCune, S. McGaughey, D. Misiukiewicz, K. Mulford, D. Nadler, E. Nunnink, J. Ohr, J. O'Malley, M. Patson, B. Paul, D. Popa, E. Powell, S. Redman, R. Rella, V. Rocha Lima, C. Sivapiragasam, A. Su, Y. Sukari, A. Wong, S. Yilmaz, E. Yorio, J.

Background: Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC), with programmed cell death ligand 1 (PD-L1) expression associated with improved response. Methods: KEYNOTE-048 was a randomised, phase 3 study of participants with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::25cb1f03a8d1b22885303ced3a20f10f
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3121788

Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences.

Autor: Tural D; Bakirköy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey. Electronic address: deniztural@gmail.com., Ölmez ÖF; Medipol University Hospital, Istanbul, Turkey., Sümbül AT; Medical Faculty, Baskent University, Adana, Turkey., Artaç M; Medical Faculty, Necmettin Erbakan University Meram, Konya, Turkey., Özhan N; Medical Faculty, Pamukkale University, Denizli, Turkey., Akar E; Bakirköy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey., Çakar B; Medical Faculty, Ege University, Izmir, Turkey., Köstek O; Medical Faculty, Trakya University, Edirne, Turkey., Ekenel M; Istanbul University Institute of Oncology, Istanbul, Turkey., Erman M; Medical Faculty, Hacettepe University, Ankara, Turkey., Coşkun HŞ; Medical Faculty, Akdeniz University, Antalya, Turkey., Selçukbiricik F; Medical Faculty, Koc University, Istanbul, Turkey., Keskin Ö; Medical Faculty, Selcuk University, Konya, Turkey., Türköz FP; MedicalPark Goztepe Hospital, Istanbul, Turkey., Oruç K; Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey., Bayram S; Antalya Training and Research Hospital, Antalya, Turkey., Yılmaz U; MedicalPark Izmir Hospital, Izmir, Turkey., Bilgetekin İ; Dr. Abdurrahman Yurtaslan Ankara OncologyTraining and Research Hospital, Ankara, Turkey., Yıldız B; Gulhane Training and Research Hospital, Ankara, Turkey., Şendur MAN; Ankara Yıldırım Beyazıt University, Faculty of Medicine, Ankara, Turkey., Paksoy N; Istanbul University Institute of Oncology, Istanbul, Turkey., Dirican A; Medical Faculty, Celal Bayar University, Manisa, Turkey., Erdem D; MedicalPark Samsun Hospital, Samsun, Turkey., Selam M; Liv Hospital, Istanbul, Turkey., Tanrıverdi Ö; Medical Faculty, Sitki Kocman University, Mugla, Turkey., Paydaş S; Medical Faculty, Cukurova University, Adana, Turkey., Urakçı Z; Medical Faculty, Dicle University, Diyarbakir, Turkey., Atağ E; Medical Faculty, Dokuz Eylul University, Izmir, Turkey., Güncan S; Medical Faculty, Mersin University, Mersin, Turkey., Ürün Y; Medical Faculty, Ankara University, Ankara, Turkey., Alkan A; Osmaniye State Hospital, Osmaniye, Turkey., Kaya AO; Medicana Hospital, Istanbul, Turkey., Özyükseler DT; Istanbul Kartal Dr. Lutfi Kirdar Training and Research Hospital, Istanbul, Turkey., Taşkaynatan H; Katip Celebi University Atatürk Training and Research Hospital, Izmir, Turkey., Yıldırım M; MedicalPark Gaziantep Hospital, Gaziantep, Turkey., Sönmez M; Ordu State Hospital, Ordu, Turkey., Başoğlu T; Medical Faculty, Marmara University, Istanbul, Turkey., Gündüz Ş; Antalya Memorial Hospital, Antalya, Turkey., Kılıçkap S; Hacettepe University Institute of Oncology, Ankara, Turkey.

Publikováno v: European urology focus [Eur Urol Focus] 2021 Sep; Vol. 7 (5), pp. 1061-1066. Date of Electronic Publication: 2020 Sep 30.